Changes in cytokine profile during local IL-2 therapy in cancer patients

被引:0
|
作者
Tomova, R
Pomakov, J
Jacobs, JJL
Adjarov, D
Popova, S
Altankova, I
Den Otter, W
Krastev, Z
机构
[1] Univ Hosp St Ivan Rilski, Gastrointestinal Clin, Sofia 1431, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Clin Immunol, Sofia 1431, Bulgaria
[3] Univ Hosp St Ivan Rilski, Dept Clin Lab, Sofia 1431, Bulgaria
[4] Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3508 TD Utrecht, Netherlands
关键词
IL-2; therapy; cytokines; IL-5; IL-10;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Exogenous interleukin 2 (IL-2) can influence the complex cytokine network in vivo. This study investigated the cytokine profile of patients with different malignancies before and after local IL-2 administration. Patients and Methods: The human TH1 / TH2 cytometric bead array (CBA) kit was used to investigate IL-2, IFN gamma, TNF alpha. IL-4, IL-5 and IL- 10 in a control group and in 13 patients. Results: The baseline serum IL-4 levels in patients were lower than in healthy controls, while the baseline ascitic IL-10 levels in patients was higher than in serum. The IL-2 applications induced a strong serum increase in IL-2 and IL-5 and even more in ascites, while IL-10 increased weakly and mainly locally. One month after the start of therapy, the serum IFN gamma had increased in patients, reaching the level of the control group. Conclusion: After local injection, IL-2 probably leaks into the blood circulation. The higher increases of IL-2, IL-5 and IL-10 in ascites compared to the serum suggests that the injected cytokines and their effects are mainly local. The minor increase of the immunosuppressive IL-10 could explain the therapeutic difference between local and systemic IL-2 therapy since IL-10 levels markedly increase after systemic IL-2 therapy. IL-5 was always increased after IL-2 therapy and, consequently, may be a downstream mediator of antitumour responses.
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [21] CLINICAL AND IMMUNE-RESPONSES OF TUBERCULOSIS PATIENTS TREATED WITH LOW-DOSE IL-2 AND MULTIDRUG THERAPY
    JOHNSON, BJ
    RESS, SR
    WILLCOX, P
    PATI, BP
    LORGAT, F
    STEAD, P
    SAHA, R
    LUKEY, P
    LAOCHUMROONVORAPONG, P
    CORRAL, L
    KAPLAN, G
    CYTOKINES AND MOLECULAR THERAPY, 1995, 1 (03): : 185 - 196
  • [22] Scheduling BCG and IL-2 Injections for Bladder Cancer Immunotherapy Treatment
    Yaniv-Rosenfeld, Amit
    Savchenko, Elizaveta
    Rosenfeld, Ariel
    Lazebnik, Teddy
    MATHEMATICS, 2023, 11 (05)
  • [23] Stem cell factor and IL-2 act synergistically in inducing intraepithelial lymphocyte proliferation and cytokine production:: Upregulation of the IL-2 receptor γ-chain and signaling via JAK-3
    Wang, T
    Alam, R
    Langley, KE
    Klimpel, GR
    CELLULAR IMMUNOLOGY, 2000, 205 (01) : 62 - 71
  • [24] Cytokines (IFNs, TNF-α, IL-2 and IL-12) and animal models of cancer
    Burke, F
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 1999, 5 (01) : 51 - 61
  • [25] Serum Level of Il-2 in Patients with Type 2 Diabetes Mellitus and Periodontopathy
    Bunjaku, V
    Popovska, M.
    Spasovski, S.
    Spasovska-Gjorgovska, A.
    Barani, M.
    Mrasori, Sh
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2022, 12 (04) : 611 - 616
  • [26] Cytokine and chemokine profile changes in patients with lower segment lumbar degenerative spondylolisthesis
    Sutovsky, Juraj
    Benco, Martin
    Sutovska, Martina
    Kocmalova, Michaela
    Pappova, Lenka
    Miklusica, Juraj
    Frano, Andrej
    Kurca, Egon
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 43 : 163 - 170
  • [27] Changes in cytokine levels in breast cancer patients with CRCI before or after CALM intervention
    Pang, Lulian
    Bi, Ziran
    Jing, Yanyan
    Yin, Xiangxiang
    Zhang, Xiuqing
    Yao, Senbang
    Zhao, Jingjing
    Cheng, Huaidong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (11): : 5415 - 5427
  • [28] Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
    Jabeen, Shakila
    Zucknick, Manuela
    Nome, Marianne
    Dannenfelser, Ruth
    Fleischer, Thomas
    Kumar, Surendra
    Luders, Torben
    Gythfeldt, Hedda von der Lippe
    Troyanskaya, Olga
    Kyte, Jon Amund
    Borresen-Dale, Anne-Lise
    Naume, Bjorn
    Tekpli, Xavier
    Engebraaten, Olav
    Kristensen, Vessela
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [29] Low-dose IL-2 therapy in autoimmune diseases: An update review
    Zhang, Ruizhi
    Zhao, Yuyang
    Chen, Xiangming
    Zhuang, Zhuoqing
    Li, Xiaomin
    Shen, Erxia
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2024, 43 (03) : 113 - 137
  • [30] Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
    Sockolosky, Jonathan T.
    Trotta, Eleonora
    Parisi, Giulia
    Picton, Lora
    Su, Leon L.
    Le, Alan C.
    Chhabra, Akanksha
    Silveria, Stephanie L.
    George, Benson M.
    King, Indigo C.
    Tiffany, Matthew R.
    Jude, Kevin
    Sibener, Leah V.
    Baker, David
    Shizuru, Judith A.
    Ribas, Antoni
    Bluestone, Jeffrey A.
    Garcia, K. Christopher
    SCIENCE, 2018, 359 (6379) : 1037 - +